124 related articles for article (PubMed ID: 17490678)
1. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo.
Ritchie RH; Quinn JM; Cao AH; Drummond GR; Kaye DM; Favaloro JM; Proietto J; Delbridge LM
J Mol Cell Cardiol; 2007 Jun; 42(6):1119-28. PubMed ID: 17490678
[TBL] [Abstract][Full Text] [Related]
2. Cytosolic, but not mitochondrial, oxidative stress is a likely contributor to cardiac hypertrophy resulting from cardiac specific GLUT4 deletion in mice.
Li Y; Wende AR; Nunthakungwan O; Huang Y; Hu E; Jin H; Boudina S; Abel ED; Jalili T
FEBS J; 2012 Feb; 279(4):599-611. PubMed ID: 22221582
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat.
Whaley-Connell A; Govindarajan G; Habibi J; Hayden MR; Cooper SA; Wei Y; Ma L; Qazi M; Link D; Karuparthi PR; Stump C; Ferrario C; Sowers JR
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E355-63. PubMed ID: 17440033
[TBL] [Abstract][Full Text] [Related]
4. Functional and metabolic remodelling in GLUT4-deficient hearts confers hyper-responsiveness to substrate intervention.
Huggins CE; Domenighetti AA; Ritchie ME; Khalil N; Favaloro JM; Proietto J; Smyth GK; Pepe S; Delbridge LM
J Mol Cell Cardiol; 2008 Feb; 44(2):270-80. PubMed ID: 18191142
[TBL] [Abstract][Full Text] [Related]
5. Targeted GLUT-4 deficiency in the heart induces cardiomyocyte hypertrophy and impaired contractility linked with Ca(2+) and proton flux dysregulation.
Domenighetti AA; Danes VR; Curl CL; Favaloro JM; Proietto J; Delbridge LM
J Mol Cell Cardiol; 2010 Apr; 48(4):663-72. PubMed ID: 19962383
[TBL] [Abstract][Full Text] [Related]
6. Renal and metabolic effects of tempol in obese ZSF1 rats--distinct role for superoxide and hydrogen peroxide in diabetic renal injury.
Rafikova O; Salah EM; Tofovic SP
Metabolism; 2008 Oct; 57(10):1434-44. PubMed ID: 18803950
[TBL] [Abstract][Full Text] [Related]
7. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
8. Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.
Woodman OL; Malakul W; Cao AH; Xu Q; Ritchie RH
Life Sci; 2008 Apr; 82(15-16):847-54. PubMed ID: 18302965
[TBL] [Abstract][Full Text] [Related]
9. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
[TBL] [Abstract][Full Text] [Related]
10. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice.
Schubert R; Erker L; Barlow C; Yakushiji H; Larson D; Russo A; Mitchell JB; Wynshaw-Boris A
Hum Mol Genet; 2004 Aug; 13(16):1793-802. PubMed ID: 15213104
[TBL] [Abstract][Full Text] [Related]
11. Altered GLUT4 translocation in skeletal muscle of 12/15-lipoxygenase knockout mice.
Vahsen S; Rakowski K; Ledwig D; Dietze-Schroeder D; Swifka J; Sasson S; Eckel J
Horm Metab Res; 2006 Jun; 38(6):391-6. PubMed ID: 16823721
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol.
Gurusamy N; Watanabe K; Ma M; Prakash P; Hirabayashi K; Zhang S; Muslin AJ; Kodama M; Aizawa Y
FEBS Lett; 2006 Apr; 580(8):1932-40. PubMed ID: 16530186
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress after uninephrectomy alters heart morphology in the apolipoprotein E -/- mouse.
Piecha G; Koleganova N; Gross ML; Geldyyev A; Ritz E
J Hypertens; 2008 Nov; 26(11):2220-9. PubMed ID: 18854764
[TBL] [Abstract][Full Text] [Related]
14. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice.
Zhang GX; Ohmori K; Nagai Y; Fujisawa Y; Nishiyama A; Abe Y; Kimura S
J Mol Cell Cardiol; 2007 Apr; 42(4):804-11. PubMed ID: 17350036
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant tempol lowers age-related increases in insulin resistance in Fischer 344 rats.
Asghar M; Lokhandwala MF
Clin Exp Hypertens; 2006 Jul; 28(5):533-41. PubMed ID: 16820349
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant Tempol enhances hypothermic cerebral preservation during prolonged cardiac arrest in dogs.
Behringer W; Safar P; Kentner R; Wu X; Kagan VE; Radovsky A; Clark RS; Kochanek PM; Subramanian M; Tyurin VA; Tyurina YY; Tisherman SA
J Cereb Blood Flow Metab; 2002 Jan; 22(1):105-17. PubMed ID: 11807400
[TBL] [Abstract][Full Text] [Related]
17. Tempol inhibits TGF-β and MMPs upregulation and prevents cardiac hypertensive changes.
Rizzi E; Castro MM; Ceron CS; Neto-Neves EM; Prado CM; Rossi MA; Tanus-Santos JE; Gerlach RF
Int J Cardiol; 2013 Apr; 165(1):165-73. PubMed ID: 21917342
[TBL] [Abstract][Full Text] [Related]
18. The nitroxide tempol has similar antioxidant effects as physiological levels of 17beta-oestradiol in reversing ovariectomy-induced oxidative stress in mice liver and kidney.
Enli Y; Oztekin O; Pinarbasili RD
Scand J Clin Lab Invest; 2009; 69(4):526-34. PubMed ID: 19343575
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant SOD mimetic prevents NADPH oxidase-induced oxidative stress and renal damage in the early stage of experimental diabetes and hypertension.
Peixoto EB; Pessoa BS; Biswas SK; Lopes de Faria JB
Am J Nephrol; 2009; 29(4):309-18. PubMed ID: 18849601
[TBL] [Abstract][Full Text] [Related]
20. Double-edged action of SOD mimetic in diabetic nephropathy.
Asaba K; Tojo A; Onozato ML; Goto A; Fujita T
J Cardiovasc Pharmacol; 2007 Jan; 49(1):13-9. PubMed ID: 17261958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
